Revance Releases Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Revance Therapeutics (RVNC) Reports In-Line Q2 EPS
August 2, 2018 5:08 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.94), in-line with the analyst estimate of ($0.94). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $510 thousand.
GUIDANCE:
Revance reiterates its financial guidance provided in January 2018.... More
